Supplementary Data from The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [&lt;sup&gt;90&lt;/sup&gt;Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial